Victor Perlroth
Known title: Chairman and CEOCIK: 0001754181
Associated companies
Transaction History
| KOD | ▲ Buy | Option Exercise | 600,000 | $3.2M | 9/25/2026 | View on chart |
| KOD | ▲ Buy | Option Exercise | 365,840 | $911K | 9/25/2026 | View on chart |
| KOD | ▲ Buy | Option Exercise | 314,684 | $1.2M | 9/25/2026 | View on chart |
| KOD | ▲ Buy | Option Exercise | 300,000 | $312K | 3/25/2026 | View on chart |
| KOD | ▼ Sell | Open Market | 340,000 | $3.1M | 2/25/2022 | View on chart |
| KOD | ▼ Sell | Open Market | 1,000,000 | $9.2M | 2/24/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 12, 2026
Kodiak Sciences (KOD) Analyst Raises Target, Presents Late‑Stage Data
HC Wainwright & Co. kept its positive stance on Kodiak Sciences and lifted its price target to $126. The company will share clinical results from three late‑stage programs at the American Academy of Ophthalmology conference. Recent reports note the stock is trading at a premium after trial news, while some analysts consider it potentially overvalued. It also appears on a list of health‑care stocks that could face difficulties in Q4.
Kodiak Sciences (KOD) Analyst Raises Target, Presents Late‑Stage Data. HC Wainwright & Co. kept its positive stance on Kodiak Sciences and lifted its price target to $126. The company will share clinical results from three late‑stage programs at the American Academy of Ophthalmology conference. Recent reports note the stock is trading at a premium after trial news, while some analysts consider it potentially overvalued. It also appears on a list of health‑care stocks that could face difficulties in Q4.